Posted on January 12, 2008 by jrowley
Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued development of their Prochymal product, and then, once the product is FDA approved for [...]
Filed under: Clinical Trials, DoD, MSCs, Osiris, Regenerative Medicine, adult stem cell, business models, stem cells | Tagged: Acute Radiation Therapy, DoD contract, Mesenchymal Stem Cell product, near term revenue, Prochymal, Type 1 diabetes | No Comments »
Posted on January 7, 2008 by jrowley
WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to expand outside the world of small molecules. This biologics expertise includes Apptec’s cell [...]
Filed under: Apptec, BD, Bioprocessing, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech, business models | 1 Comment »
Posted on January 2, 2008 by jrowley
With the New Year upon us, I thought it would be good to make a set of New Year’s Resolutions for the regenerative medicine industry. This set of resolutions is not company specific, but things that will be required to build long term value for this nascent industry.
Get those marketing people working: Any [...]
Filed under: Innovation, Regenerative Medicine, business models | Tagged: business models, convergent biological technologies, new year's resolutions, strategic marketing | 2 Comments »
Posted on December 19, 2007 by jrowley
There have been some interesting news releases this week, including Osiris’ fast track designation, Cytori obtaining a 510k for their fat cleaner (not their stem cell isolation device, just a clinical fat cleaner), and the angiogenesis and liver regeneration capabilities of Aldagen’s aldehyde dehydrogenase positive sorted cells. However, the press release that really caught my [...]
Filed under: BioTime, Bioprocessing, Embryome Sciences, Regenerative Medicine, business models | Tagged: bioprocess supply, BioTime, business model, Embryome Sciences, Michael West, spinnout | No Comments »
Posted on December 13, 2007 by jrowley
Organogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and it was launched by a Harvard/MIT-trained plastic surgeon, Dr. Yiling Cao. The two companies [...]
Filed under: Bioprocessing, Joint Ventures, Manufacturing, Regenerative Medicine, business models | Tagged: china, China's National Tissue Engineering Center, joint venture, Organogenesis, Regenerative Medicine | 1 Comment »
Posted on December 9, 2007 by jrowley
The regenerative medicine industry is banking on cellular therapy to help regenerate tissues and restore function in clinical indications with high unmet needs. The mechanism of action, or how stem cells actually drive tissue regeneration, is still hotly debated - but it is likely a mixture of several actions (see item #6 in this post) [...]
Filed under: Biomaterials, Regenerative Medicine, business models | Tagged: biomaterials as therapeutics, business models, Regenerative Medicine | 1 Comment »
